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Abstract
Objective To compare the cost effectiveness of the threemost commonly
chosen types of prosthesis for total hip replacement.
Design Lifetime cost effectiveness model with parameters estimated
from individual patient data obtained from three large national databases.
Setting English National Health Service.
Participants Adults aged 55 to 84 undergoing primary total hip
replacement for osteoarthritis.
Interventions Total hip replacement using either cemented, cementless,
or hybrid prostheses.
Main outcome measures Cost (£), quality of life (EQ-5D-3L, where 0
represents death and 1 perfect health), quality adjusted life years
(QALYs), incremental cost effectiveness ratios, and the probability that
each prosthesis type is the most cost effective at alternative thresholds
of willingness to pay for a QALY gain.
Results Lifetime costs were generally lowest with cemented prostheses,
and postoperative quality of life and lifetime QALYs were highest with
hybrid prostheses. For example, in women aged 70 mean costs were
£6900 ($11 000; €8200) for cemented prostheses, £7800 for cementless
prostheses, and £7500 for hybrid prostheses; mean postoperative EQ-5D
scores were 0.78, 0.80, and 0.81, and the corresponding lifetime QALYs
were 9.0, 9.2, and 9.3 years. The incremental cost per QALY for hybrid
compared with cemented prostheses was £2500. If the threshold
willingness to pay for a QALY gain exceeded £10 000, the probability
that hybrid prostheses were most cost effective was about 70%. Hybrid
prostheses have the highest probability of being the most cost effective
in all subgroups, except in women aged 80, where cemented prostheses
were most cost effective.
Conclusions Cemented prostheses were the least costly type for total
hip replacement, but for most patient groups hybrid prostheses were the
most cost effective. Cementless prostheses did not provide sufficient
improvement in health outcomes to justify their additional costs.
Introduction
Total hip replacement is one of the most common surgical
procedures. In 2010 the global market for hip prostheses was
estimated at $4.7b (£3.0b; €3.5b).1 A large number of different
prosthesis designs have been developed and introduced on the
market. For example, in England and Wales in 2010 at least
123 different brands of acetabular cups and 146 brands of
femoral stems were used.2 These prosthesis brands are often
grouped into cemented, cementless, and hybrid prostheses.
Hybrid prostheses consist of cemented stems and cementless
cups.
Cementless prostheses, although the most expensive, have
become the most common type of prosthesis used for total hip
replacement in England, Wales, Italy, Australia, Canada, and
the United States, with hybrid prostheses growing in
popularity.2-6 The increasing use of cementless components has
contributed to a doubling of prosthesis costs between 1996 and
2006.7Although a recent study analysing data from the National
Joint Registry for England and Wales, the largest orthopaedic
registry in the world, suggested that cementless prostheses might
be associated with lower mortality than cemented prostheses,8
evidence to assess whether the increased costs of cementless
components are justified by improved health outcomes is
lacking.
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Randomised controlled trials have compared revision rates
across prosthesis types, but with insufficient sample sizes or
durations of follow-up to produce conclusive results.9The largest
observational study found that seven year revision rates were
lower for cemented (3.0%) than for hybrid (3.8%) or cementless
prostheses (4.6%).2
Previous economic evaluations comparing prosthesis types
suggested that cementless prostheses are relatively cost
effective.10-12 These studies did not, however, consider
differences between prosthesis types in preoperative case mix11
or postoperative quality of life.10 12
We evaluated the relative cost effectiveness of cemented,
cementless, and hybrid prostheses for elective total hip
replacement surgery. The study took a health service perspective
and presents lifetime cost effectiveness results for men and
women aged 60, 70, and 80. To overcome the deficiencies of
earlier economic analyses, we used data on case mix and quality
of life from a national programme that collects patient reported
outcome measures in patients undergoing an elective total hip
replacement in the English National Health Service,13 linked to
records of the national joint registry.
Methods
Model overview
We used a Markov model with a cycle length of one year to
simulate transitions between health states over the patients’
lifetime.14 For each prosthesis type we estimated costs and
outcomes for a hypothetical cohort of patients who enter the
model at the time of the primary total hip replacement (fig 1⇓).
After the primary replacement, patients face a possibility of
immediate postoperative mortality and annual probabilities of
revision of the total hip replacement (one stage or two stage)
and all cause mortality. If a prosthesis fails, the model assumes
patients will have their hip prosthesis revised.
We summed the time in each health state over the annual cycles,
weighted for quality of life, to estimate life expectancy in terms
of quality adjusted life years (QALYs). Lifetime costs were
calculated by adding costs that were related to the primary hip
replacements to the costs of one stage and two stage revisions.
The main model assumptions, summarised in the box, were
taken from a previous cost effectiveness analysis.15 In sensitivity
analyses we tested whether our results are robust to alternative
assumptions. We describe data sources and statistical analyses
for the main model parameters.
Data sources
Overview
For the cost effectiveness analysis model we estimated several
parameters from individual patient data: quality of life (after
primary total hip replacement, revised total hip replacement),
length of stay after primary total hip replacement, rates of
revision and re-revision, and mortality. The three data sources
used were the national patient reported outcome measures
programme, the National Joint Registry for England andWales,
and hospital episode statistics. Hospital episode statistics is the
administrative database of all NHS funded hospital admissions
in England.16
We used data on patient reported outcome measures for the
estimation of quality of life after each type of total hip
replacement. As we required data from the joint registry to
categorise prosthesis type, we excluded those records on patient
reported outcome measures without a record linked to the
registry. All patient reported outcome measures entries with a
joint registry record were also linked to hospital episode
statistics (patient reported outcome measures, national joint
registry, and hospital episode statistics data). From these linked
records we estimated the length of stay after total hip
replacement. We considered primary and revision operations
separately.
To provide the most accurate estimates of revision rates within
the first five years by prosthesis type, we used the joint registry
data but excluded patients without a linked record to hospital
episode statistics (joint registry and hospital episode statistics
data). From unlinked data in hospital episode statistics we
estimated the rates of revision after five years, re-revision, and
mortality (hospital episode statistics only). See the
supplementary file for further information on data sources and
exclusion criteria required to estimate each parameter.
Quality of life, preoperative characteristics, and
prosthesis type
We obtained data on quality of life from patients who had an
elective total hip replacement between July 2008 and December
2010 in the English NHS.13 The database of patient reported
outcomemeasures provided data on comorbidities, preoperative
and postoperative symptoms and disability (Oxford hip score),
and quality of life (EQ-5D-3L). The Oxford hip score is a
disease specific instrument with 12 questions and responses
expressed on a four point scale to produce an overall score
ranging from 0 (worst health status) to 48 (best health status).17
The EQ-5D-3L is a generic instrument with five dimensions of
health (mobility, self care, usual activities, pain and discomfort,
anxiety and depression) and three levels (no problems, some
problems, severe problems). We combined the EQ-5D-3L
profiles with health state preference values from the UK general
population, to give EQ-5D-3L utility index scores on a scale
anchored at 0 (death) and 1 (perfect health).18 We accessed
preoperative records on patient reported outcome measures for
73 666 adults after excluding those aged under 55 or over 84,
and we subsequently included 39 734 patients with a linked
joint registry record in the estimation of quality of life after
primary total hip replacement. The joint registry provided data
on prosthesis type, diagnosis (osteoarthritis or other), bodymass
index, and American Society of Anesthesiologists (ASA) grade
for physical status.19 Hospital episode statistics provided data
on socioeconomic deprivation, derived from the patient’s
postcode, as the index of multiple deprivation.20 We used five
socioeconomic groups based on fifths of the national ranking
of areas with an average population of 1500 people.
For the estimation of quality of life after primary total hip
replacement, we excluded those who did not have a diagnosis
of osteoarthritis; who received prostheses with a cementless
stem and a cemented acetabular cup, or a hip resurfacing
prosthesis; who had bone grafts; who had image guided or
minimally invasive surgery; who had a bilateral procedure; or
whose joint replacement was privately funded.We also excluded
patients who had died, because death is captured separately in
theMarkov model. The resulting sample of 30 203 patients was
used to estimate quality of life six months after each type of
total hip replacement. The model applies these quality of life
estimates to patients in the primary total hip replacement health
state in the initial cycle and each subsequent cycle.
For the health state during the year in which patients had a
revision total hip replacement because of a prosthesis failure,
we took quality of life from data on preoperative patient reported
outcome measures for 2105 patients with linked data between
patient reported outcome measures, joint registry, and hospital
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Main assumptions in cost effectiveness analysis
• Patients enter the model at the time they have the total hip replacement. The model assumes that the postoperative quality of life
observed at six months applies from when the patients enter the model and to subsequent model cycles in the total hip replacement
health state
• The differences observed in quality of life across prosthesis types six months after total hip replacement is maintained for the lifetime,
subject to the decline in quality of life with increasing age and the possibility that the total hip replacement fails
• The approach to estimate the effect of prosthesis type on quality of life has fully addressed confounding
• Deterioration of the prosthesis does not affect quality of life adversely unless the prosthesis is revised
• All failed prostheses are revised
• The effect of prosthesis failure on quality of life is estimated from the quality of life observed before surgery in those who had a revision,
and is applied for one year after revision
• The approach to extrapolate prosthesis survival beyond the observed data accurately predicts the long term probability of prosthesis
survival
• The costs of revising the total hip replacement are the same for each type of primary total hip replacement
• Quality of life after revision is the same whether or not the revision was undertaken as a result of sepsis
episode statistics who had a revision. For subsequent years after
revision, when patients were assumed to be in the revised total
hip replacement health state, we took quality of life from the
linked data collected for 1283 patients six months after revision
surgery.
Rates of revision and re-revision
To estimate revision rates we exploited access to all of the joint
registry records on total hip replacement since inception in 2003
until December 2009 and hospital episode statistics data from
April 1997 until December 2009. Where possible we linked the
patient records in the joint registry to the corresponding record
in hospital episode statistics to create a linked dataset for these
two repositories. From these linked records we estimated the
annual probabilities of revision in the first five years after total
hip replacement. From the joint registry we accessed 289 785
records of patients who had a primary total hip replacement
between 1 April 2003 and 31 December 2009, of which 216
693 could be linked to hospital episode statistics. Records for
144 661 patients were available for analysis after applying the
same exclusion criteria applied to the dataset of patient reported
outcome measures, joint registry, and hospital episode statistics
linked records. We considered a patient to have had a revision
if we found a record of revision surgery in either the joint
registry or hospital episode statistics. Overall, 2023 revisions
were identified: 866 for cemented prostheses (1.2%), 817 for
cementless prostheses (1.8%), and 340 for hybrid prostheses
(1.4%). Data capture in the joint registry was poor before 2005,
hence revision rates after five years were based on data from
hospital episode statistics only. After applying the previously
mentioned exclusion criteria for age and diagnosis we identified
201 655 eligible patients who had a primary total hip
replacement carried out between 1March 1997 and 24December
2004. We estimated the rates of re-revision from the records of
54 134 patients with a revision recorded in hospital episode
statistics between April 1997 and December 2009.
Mortality
Mortality (surgical and all cause) in the year after total hip
replacement was estimated from hospital episode statistics data.
Subsequent annual mortality (all cause) according to age and
sex was taken from general population data, after using
information from hospital episode statistics data to adjust for
the “healthy patient” effect, given that patients who undergo a
total hip replacement are likely to have a slightly lower mortality
than that observed in the general population.21 We did not find
any difference inmortality across prosthesis types after adjusting
for potential confounders (age, sex, ASA grade, body mass
index, articulation type, funding source, and date of surgery).
The hazard rate for mortality after total hip replacement using
cemented versus cementless prostheses was 1.01 (P=0.75), and
so we applied the same probabilities of death across all
prosthesis types.
Costs
The unit cost of each prosthesis type was taken from the prices
paid by a typical NHS provider for the most popular implant
systems, including all components and instrumentation. These
prices were lower than list prices. We calculated unit costs for
each prosthesis type byweighting the price for each brandwithin
the different types according to each brand’s relative frequency,
assuming a standard metal-on-polythene articulation: £739 for
a cemented prosthesis, £1697 for a cementless prosthesis, and
£1285 for a hybrid prosthesis.
Costs of the operation theatre and hospital stay were based on
a national study,22modified by using the length of stay according
to prosthesis type that we observed in the patient reported
outcome measures, joint registry, and hospital episode statistics
linked records (n=30 203), and assuming a cost per hospital day
of £225.23 Unit costs of revisions are generally higher than for
the initial surgery24; here we multiplied the average total cost
of a primary total hip replacement by a factor that differed
according to the reason for revision (3.6 for two stage revisions
and 1.4 for one stage revisions).25 All unit costs were reported
in British pounds (£1.00; $1.60; €1.20) according to 2010-11
prices.
Statistical analysis to provide input
parameters for cost effectiveness model
Quality of life after primary total hip replacement
and revision
We estimated quality of life following primary total hip
replacement according to prosthesis type after adjusting for
observed differences in preoperative characteristics between
the comparison groups. For the adjustment we used both Genetic
Matching (GenMatch) and regression. GenMatch is a
multivariate matching method that aims to make the distribution
of baseline characteristics as similar as possible,26 and it has
previously been used in evaluating relative effectiveness and
cost effectiveness.27-29 GenMatch selects matched pairs using a
generalised Mahalanobis distance metric, which weights each
baseline covariate included in the matching. The weights define
alternative distance metrics, which differ in the relative
importance given to matching each covariate. The automated
search algorithm selects those weights (and hence the
corresponding distance metric) that give the best covariate
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balance in the matched samples. The balance statistics are
chosen, a priori, from recommendedmeasures such as t statistics
from paired t tests, D statistics fromKolmogorov-Smirnov tests,
and weighted standardised differences. The search algorithm
optimises the balance between covariates within the constraints
of the data. Compared with propensity score matching,
GenMatch has been shown to reduce imbalance between
covariates and bias from confounding.26 27 30
For patients receiving each prosthesis type, we used GenMatch
to find the best match from each of the other two prosthesis
groups. Patients were matched on age, sex, number of
comorbidities, body mass index, disability, ASA grade, index
of multiple deprivation, preoperative EQ-5D-3L and Oxford
hip scores, surgeon experience (senior surgeon or not), and
hospital type (treatment centre or not). All matching was
performed as nearest neighbour matching one to one with
replacement. We used linear regression to adjust for any
remaining imbalance and to predict postoperative quality of life
by prosthesis type for each subgroup (for men and women aged
60, 70, and 80). The model included the above covariates but
with ASA grade categorised as grades 1, 2, and 3-5, and body
mass index (weight (kg)/(height (m)2)) as less than 30, 30-35,
and greater than 35. The model also included quadratic terms
for age, and quadratic and cubic terms for preoperative
EQ-5D-3L scores. We defined reference groups by the average
preoperative quality of life for each subgroup, a body mass
index lower than 30, and an ASA grade of 2 (mild systemic
disease).
We used regression to predict the mean quality of life in the
year of revision surgery as a function of age, sex, and type of
revision (one stage or two stage). Regression was also used to
predict the mean quality of life after revision as a function of
age and sex.
To estimate the effect of aging on quality of life after primary
total hip replacement we applied an ordinary least squares
regression model using data from the medical expenditure panel
survey.31 We found that EQ-5D-3L scores declined by on
average 0.0033 for an increase in age of one year. Hence, quality
of life after primary total hip replacement was reduced by 0.0033
for each year that patients survived beyond the first. As quality
of life after revision was already parameterised as a function of
age, we did not undertake further adjustment for aging.
Of the 30 203 patients included in the quality of life analysis,
data were missing on body mass index for 36% and on
postoperative patient reported outcome measures for 33%. All
other data items were complete for over 90% of the sample. We
applied multiple imputation using chained equations to
preoperative and postoperative data to impute missing
responses.32 Five imputations were undertaken and we used
Rubin’s rules to combine the results across these imputations.
Rates of revision and re-revision
The annual revision rates within the first five years were
predicted from linked joint registry and hospital episode statistics
data for each prosthesis type, adjusted for case mix (age, sex,
ASA grade, and bodymass index).We used a piecewise constant
survival regression model, which assumes constant hazards
within one year periods to capture the underlying variation in
revision rates over timewithout imposing a prespecified relation.
Revisions predicted by the survival model were further classified
as one stage or two stage. We predicted the probability of
whether or not the revision of a prosthesis was one stage
according to joint registry classifications, with logistic
regression.
Revision rates for cemented and cementless prostheses beyond
five years after the total hip replacement were predicted by
fitting a survival model with a Weibull hazard function to
patients in hospital episode statistics with five to 12 years of
follow-up data, adjusting for age and sex. Comparison of records
in hospital episode statistics alone with the joint registry and
hospital episode statistics linked record indicated a slightly
lower capture of revisions in the absence of joint registry
linkage. Consequently, we applied a weighting factor of 1.15
to revision probabilities estimated from hospital episode
statistics. The hospital episode statistics data do not identify
hybrid prostheses as a distinct category before 2006, so after
five years we assumed the revision rates for hybrid prostheses
were the same as for cemented or cementless prostheses,
whichever was the highest.
Re-revision rates were estimated with a piecewise constant
survival regression model, which allowed for different revision
rates in the first year versus subsequent years. All re-revisions
were assumed to be one stage revisions.
Regression analysis was undertaken in Stata version 12.Markov
modelling was undertaken in Microsoft Excel.
Cost effectiveness analysis
The cost effectiveness model estimated lifetime revision rates,
costs related to total hip replacement, and QALYs for men and
women aged 60, 70, and 80, according to the reference group
defined in the regression models (the average preoperative
quality of life for each subgroup, body mass index <30, and
ASA grade 2). We report the incremental costs per QALY and
the probability that each prosthesis type is the most cost
effective. By undertaking a probabilistic analysis we recognised
sampling uncertainty around the model parameters. Model
results are reported after averaging across 1000 simulations in
which each model parameter was sampled from the appropriate
probability distribution.
In each simulation the net monetary benefit was calculated for
each prosthesis type by multiplying the lifetime QALYs by
society’s willingness to pay for a QALY gain and subtracting
from this the total lifetime cost. The willingness to pay
thresholds ranged from £0 to £50 000. We calculated cost
effectiveness acceptability curves to report the proportion of
simulations that each prosthesis type is the most cost
effective—that is, had the highest net monetary benefit—as a
function of the threshold willingness to pay. Future costs and
outcomes should be valued less than costs and outcomes
immediately after the total hip replacement to reflect societal
time preferences. We applied a recommended annual discount
rate of 3.5% to both costs and outcomes.
Sensitivity analyses
We tested whether our results were robust to alternative
assumptions. Firstly, the base case model assumes that in the
absence of a prosthesis failure, any differences in quality of life
between prosthesis types are maintained over the patient’s
lifetime. Here we assumed instead that any residual differences
in quality of life between the prosthesis types are maintained
for two years after the total hip replacement. Secondly, to
consider an alternative way of addressing potential confounding,
we estimated postoperative quality of life with ordinary least
squares regression but without using GenMatch. Thirdly, we
predicted revision rates beyond five years using a Gompertz
rather than a Weibull hazard function. Fourthly, we created a
“failed hip” state, whereas in the base case analysis we assumed
that all patients with a prosthetic failure had a revision. Patients
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were assumed to move to this failed hip state if their prosthesis
failed and their risk of operative mortality was predicted to
exceed 10%. Quality of life for this failed hip state was assumed
to be that for patients awaiting revision surgery. Fifthly, in the
light of recent concerns over the use of metal-on-metal
prostheses33we undertook a sensitivity analysis in which quality
of life and revision rates after total hip replacement were
estimated after exclusion of patients with these prostheses.
Results
Patient characteristics before total hip
replacement
Of the 30 203 patients included in the analysis of quality of life
after total hip replacement, those who received a cemented
prosthesis were on average older, more likely to be women, and
to have more comorbidities and a higher ASA grade than those
who received another prosthesis type (table 1⇓). The mean
preoperative Oxford hip score and EQ-5D-3L index score were
slightly higher in the group that received cementless or hybrid
prostheses.
Initial outcomes and costs after primary total
hip replacement
After matching, the preoperative characteristics were well
balanced across the comparison groups. In 70 year old men and
women, the mean quality of life six months after the primary
total hip replacement was predicted to be lowest with cemented
prostheses and highest with hybrid prostheses (table 2⇓). The
differences in postoperative outcome across prosthesis types
were reflected in both quality of life (EQ-5D-3L index score)
and hip symptoms and function (Oxford hip score). The same
pattern was observed in 60 year old men and women and 80
year old men.
Results from the sensitivity analysis in which ordinary least
squares regression was undertaken without GenMatch gave
similar results to the base case. Hybrid prostheses were predicted
to provide the highest postoperative quality of life for all
subgroups except women aged 80.
In men and women aged 70 and 80 revision rates at five and 10
years were lowest with cemented prostheses and highest with
cementless prostheses. Only in 60 year old menwere cementless
prostheses competitive in terms of 10 year revision rates. In all
subgroups, initial costs were lowest with cemented prostheses
and highest with cementless prostheses.
Cost effectiveness analysis
In men and women aged 70 the average lifetime costs related
to total hip replacement were lowest with cemented prostheses
and highest with cementless prostheses (table 3⇓). In this age
group, patients with cementless or hybrid prostheses had slightly
higher expected QALYs. Hybrid prostheses were reported to
produce higher expected QALYs at lower overall cost than
cementless prostheses. The incremental cost effectiveness ratio
for a hybrid prosthesis compared with a cemented prosthesis
was about £2100 per QALY for men and £2500 for women.
Similarly, the cost effectiveness acceptability curves in figure
2⇓ and the values in table 4⇓ show that hybrid prostheses were
most likely to be cost effective for patients aged 70—that is,
hybrid prostheses were associated with the highest net monetary
benefit in most of the 1000 simulations in the probabilistic
model. If the societal willingness to pay per QALY was £10
000 or higher, the probabilities that hybrid prostheses were the
most cost effective prosthesis type were about 75% for men and
70% for women. The corresponding probabilities for cementless
prostheses were about 25% for men and 30% for women, and
around 1% for cemented prostheses.
For men aged 60 or 80 and for women aged 60, hybrid
prostheses gave the highest expected net benefit and had the
highest probability of being the most cost effective prosthesis
type (fig 2 and table 4). For women aged 80, cemented
prostheses were most cost effective.
Sensitivity analyses
The base case model was generally robust, in that the pattern
of results remained similar with alternative assumptions, even
if metal-on-metal prostheses were excluded (table 5⇓). However,
when the difference in quality of life between prosthesis types
was assumed to last only two years, the pattern changed, but
hybrid prostheses remained likely to be the most cost effective
option for men and women aged 70.
Discussion
In patients aged 70, which is about the mean age of those
undergoing a total hip replacement for osteoarthritis, the
incremental costs per quality adjusted life year (QALY) for
hybrid prostheses comparedwith cemented prostheses was about
£2100 for men and £2500 for women. In all subgroups, apart
fromwomen aged 80, hybrid prostheses resulted in higher mean
postoperative quality of life than cementless or cemented
prostheses, and so have higher lifetime QALYs. At realistic
levels of willingness to pay for a QALY gain, the probability
that hybrid prostheses are the most cost effective option is
around 75% for patients aged 70. In patients aged 60 and 80,
the cost effectiveness results were less clear cut, but for 70 year
olds the finding that the hybrid type of prosthesis was the most
cost effective alternative was robust to alternative assumptions.
Comparison with other studies
The results of our cost effectiveness analysis differ from those
of three previous economic evaluations, which suggested that
cementless prostheses were cost effective compared with
cemented11 12 or hybrid prostheses.10 However, all those studies
had serious methodological shortcomings. Only one study
measured postoperative quality of life according to prosthesis
type,11 but it was based on a small sample of patients (n=363),
did not include hybrid prostheses, was undertaken about two
decades ago, and did not adjust for differences in key case mix
factors such as preoperative quality of life and age. A second
study did not seem to adjust for age when comparing revision
rates across prostheses types, despite age differences of 4.5
years.10 The third study presented results that were inconsistent
with their model parameters.12
Strengths and limitations of this study
Our cost effectiveness study had several strengths. Firstly, we
estimated revision rates and postoperative quality of life by
prosthesis type from large national studies. These sources
provided detailed information about the patients’ preoperative
condition. Although the estimation of postoperative quality of
life and five year revision rates required national joint registry
linked data, our sample was representative of the target
population of interest. Secondly, we used GenMatch, a
sophisticated multivariate matching approach, combined with
regression, to improve the case mix adjustment when estimating
postoperative quality of life, a key driver of the cost
effectiveness results. Thirdly, in taking a recommended decision
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analytical approach,15 we refined the structure of a previous
model by allowing prosthesis failure to occur in the first year
after the primary hip replacement or after revision surgery. We
also distinguished between one and two stage revisions.
Fourthly, our key model estimates represent current practice.
The estimates of the revision rates, quality of life, and mortality
were derived from patients who have undergone a hip
replacement since 1997. This is potentially important as over
the last two decades revision rates have decreased considerably.34
Fifthly, our cost estimates are based on the actual prices paid
by mid-sized centres in the English NHS, as well as on the
length of hospital stay observed for the different prosthesis
types. Finally, we undertook a full probabilistic sensitivity
analysis to ensure that the sampling uncertainties in the model
parameters were fully represented in the results. We then tested
the results’ sensitivity to key assumptions.
A crucial step in the analysis was the estimation of lifetime
outcomes. Lifetime revision rates were derived from the
National Joint Registry of England andWales and administrative
data from all relevant hospital admissions to the English NHS
with a maximum follow-up of 13 years, which provided a
stronger basis for extrapolation than previous studies.10-12 A
potential concern is the assumption that differences in quality
of life observed at six months after the joint replacement remain
unchanged for the rest of a patient’s life, after allowing for
increasing age and any differential revision rates between
prosthesis types. The sensitivity analysis demonstrated that if
the residual differences in postoperative quality of life were
assumed to last for only two years, then the probability that
cemented prostheses are cost effective increased. However,
there is evidence that the quality of life improvements after total
hip replacement persists for at least five years.35
We found that quality adjusted life expectancy was not only
highest for hybrid prostheses but that this prosthesis type also
had the highest lifetime revision rate. This shows that
postoperative quality of life is an important driver of our results.
It is therefore reassuring that the results from using the quality
of life measure (EQ-5D-3L) are consistent with those of a
disease specific score (Oxford hip score) that measured severity
of symptoms and function. Unlike a previous study, our analysis
of linked data from the national joint registry and hospital
episode statistics with adjustment for patients and prosthesis
characteristics, showed no difference in mortality across
prosthesis types.8
This study has some limitations. Firstly, while we used the best
available information on postoperative quality of life, and a
sophisticated matching method to allow for all well recognised
preoperative case mix factors, the possibility of bias from
residual confounding remains. Secondly, previous work has
highlighted that long term predictions from parametric survival
models can be inaccurate.36 While this remains a concern, the
sensitivity analysis found that the results were robust to the
choice of extrapolation approach. Thirdly, this cost effectiveness
analysis compared alternative prosthesis types; it did not
consider that revision rates within a prosthesis type may differ
by brand.2 Further research following the approach taken here
will explore the lifetime cost effectiveness of alternative brands.
Similarly, future studies will assess whether the additional costs
of newer, more costly, joint bearing surfaces commonly used
with cementless prostheses, are justified by improved revision
rates or quality of life.
Conclusions
This study questions the increased use of cementless prostheses
for total hip replacement. Cemented prostheses are the cheapest
option, but hybrid prostheses lead to greater gains in mean
postoperative quality of life and are the most cost effective
alternative for most patients. Cementless prostheses do not
improve health outcomes sufficiently to justify their higher
costs.
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Tables
Table 1| Preoperative characteristics of 30 203 patients with linked records from patient reported outcomemeasures, National Joint Registry
for England andWales, and hospital episode statistics after multiple imputation. Values are numbers (percentages) unless stated otherwise
Data source
Prosthesis type
Characteristics HybridCementlessCemented
National joint registry355114 69711 955No of patients
70.4 (7.2)67.8 (7.2)72.4 (6.7)Mean (SD) age (years)
National joint registry2201 (62.0)8149 (55.4)7760 (64.9)Women
Hospital episode statistics874 (24.6)2856 (19.4)2309 (19.3)Most deprived fifth*
Patient reported outcome measures866 (24.4)3197 (21.8)2309 (25.0)≥2 comorbidities†
National joint registry558 (15.7)1815 (12.3)2102 (17.6)ASA grade ≥3
National joint registry28.8 (5.56)29.2 (5.42)28.7 (5.37)Mean (SD) body mass index
Hospital episode statistics173 (4.9)1566 (10.7)1099 (9.2)Hip replacement at independent sector treatment centre
National joint registry2871 (80.9)12 649 (86.1)9873 (82.6)Hip replacement by consultant
Patient reported outcome measures18.1 (8.16)18.3 (8.24)17.7 (8.12)Mean (SD) preoperative Oxford hip score
Patient reported outcome measures0.34 (0.32)0.36 (0.32)0.34 (0.32)Mean (SD) EQ-5D-3L index‡
ASA=American Society of Anesthesiologists.
*Multiple index of deprivation.
†Excludes osteoarthritis.
‡0 represents death and 1 perfect health.
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Table 2| Initial cost of surgery, quality of life* six months after total hip replacement, and revision rates according to prosthesis type
Age 80Age 70Age 60
Variables HybridCementlessCementedHybridCementlessCementedHybridCementlessCemented
Men:
0.8240.8040.7970.8480.8360.8190.8100.8070.797EQ-5D-3L index
41.140.439.741.641.040.440.940.440.0Oxford hip score
698972276459671169196096661068115996Initial cost (£)†
3.33.31.82.32.92.02.53.12.45 year revision
rate‡ (%)
4.74.53.35.15.24.86.96.76.710 year revision
rate§ (%)
Women:
0.7510.7490.7540.8050.7990.7810.8000.7870.785EQ-5D-3L index
38.338.438.340.340.039.140.340.139.8Oxford hip score
712673516581682270186193669468826065Initial cost (£)†
2.73.11.41.92.81.52.12.91.85 year revision
rate‡ (%)
3.84.02.54.04.53.65.35.65.110 year revision
rate§ (%)
*After applying GenMatch and regression to allow for observed preoperative differences.
†Combined costs of prosthesis, operating theatre, and hospital stay.
‡After adjusting for case mix by applying piecewise constant hazards model to linked data from the National Joint Registry of England and Wales and hospital
episode statistics.
§After adjusting for case mix by applying piecewise constant hazards model to linked data from the National Joint Registry of England and Wales and hospital
episode statistics, (years 1-5) and by applying Weibull hazard function to data from hospital episode statistics (years 6-10).
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Table 3| Estimated lifetime revision rates, replacement related cost, and quality adjusted life years (QALYs) according to prosthesis type
for men and women aged 60, 70, and 80
Mean QALYsMean cost (£)Proportion revised (%)
Sex and age HybridCementlessCementedHybridCementlessCementedHybridCementlessCemented
Men:
11.2311.2111.0687268748816731.728.531.760
8.758.638.467516771269129.59.09.270
5.385.255.227481769068194.34.13.080
Women:
11.9011.7311.6984878551786429.526.529.360
9.259.188.997486770468378.68.48.370
5.785.755.827521776268533.94.02.780
£1.00 ($1.60; €1.20) according to 2010-11 prices.
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Table 4| Probability that a prosthesis type is cost effective at alternative willingness to pay thresholds for men and women aged 60, 70,
and 80
Willingness to pay thresholds
Sex and age
£30 000£20 000£10 000
HybridCementlessCementedHybridCementlessCementedHybridCementlessCemented
Men:
0.500.380.120.500.370.130.490.350.1660
0.750.240.010.760.230.010.760.210.0470
0.860.120.030.850.110.040.800.070.1380
Women:
0.650.140.210.650.130.220.620.110.2760
0.730.260.010.740.250.010.740.230.0370
0.230.100.670.200.080.720.130.030.8580
£1.00 ($1.60; €1.20) according to 2010-11 prices.
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Table 5| Sensitivity analysis. Probability that each prosthesis type is cost effective under alternative assumptions at a willingness to pay
threshold of £20 000 per quality adjusted life year (QALY) for men and women aged 60, 70, and 80
Prosthesis type
Analyses by sex and age HybridCementlessCemented
QoL analysis using linear regression without matching
Men:
0.810.060.1360
0.900.090.0070
0.420.220.3680
Women:
0.680.080.2460
0.930.070.0170
0.310.110.5880
Differences in QoL by prosthesis type maintained for 2 years
Men:
0.300.440.2660
0.690.090.2370
0.410.010.5880
Women:
0.390.160.4560
0.540.030.4470
0.010.000.9980
“Failed hip” state for patients with high operative mortality
Men:
0.520.370.1260
0.770.220.0170
0.830.110.0780
Women:
0.630.140.2360
0.720.280.0170
0.230.080.6980
Extrapolating revision rates using Gompertz hazard
Men:
0.490.400.1260
0.750.240.0170
0.810.130.0680
Women:
0.630.160.2160
0.730.260.0170
0.210.080.7180
Exclusion of patients with metal-on-metal prostheses
Men:
0.480.400.1160
0.800.190.0170
0.920.000.0880
Women:
0.620.120.2660
0.730.260.0170
0.240.070.6980
QoL=quality of life.
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Table 5 (continued)
Prosthesis type
Analyses by sex and age HybridCementlessCemented
£1.00 ($1.60; €1.20) according to 2010-11 prices.
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Figures
Fig 1 Markov model for cost effectiveness analysis of alternative prostheses types for primary total hip replacement
Fig 2 Cost effectiveness acceptability curves for cemented, cementless, and hybrid prostheses for total hip replacement
by subgroup plotted for alternative threshold willingness to pay for a quality adjusted life year (QALY) gained
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